Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 CRISPR-Cas9 applied in the adoptive therapy in clinical trials

From: CRISPR–Cas9 applications in T cells and adoptive T cell therapies

Target locus

Tumor

Antigen

References

TCR PD1

Pleural mesothelioma, ovarian carcinoma, pancreatic ductal adenocarcinoma

Mesothelin CAR

[90, 94]

PD1

r/r aggressive B cell non-Hodgkin’s lymphoma, r/r non-Hodgkin’s lymphoma

CD19 CAR

[185] [149]

CD52 TRAC

r/r CD19-positive B cell acute lymphoblastic leukemia (B-ALL)

CD19 CAR

[126]

TRAC CD52

r/r acute lymphoblastic leukemia (r/r ALL)

CD19/CD22 CAR

[150]

CD52 TCRβ CD7

Acute lymphoblastic leukemia

CD7 CAR

[151]

TRAC TRBC

Myeloma, non-small cell lung cancer, ovarian, breast

NeoTCRs

[110]

TRAC TRBC PD1

Refractory myeloma; metastatic sarcoma

NY-ESO-1(TCR-T)

[85]

PD1

Advanced non-small cell lung cancer

TIL

[152]

  1. r/r relapsed/refractory
Back to article page

Cellular & Molecular Biology Letters

ISSN: 1689-1392

Contact us